| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The NHS ester functional group on Cyanine5 NHS ester chloride targets primary amines (-NH₂) on biomolecules such as proteins, antibodies, and peptides. The compound does not target specific enzymes or receptors but serves as a covalent labeling reagent that attaches the Cy5 fluorophore to amine-containing biomolecules.
|
|---|---|
| ln Vitro |
End-capping Poly(β-amino esters) (pBAEs) backbones are achieved by reacting the free amino group on the cysteine amino acid with cyanine-5 NHS ester amine-reactive red emitting fluorescent dye[1].
The in vitro activity of Cyanine5 NHS ester chloride is characterized by its strong far-red fluorescence, with excitation and emission maxima around 646 nm and 662 nm. The far-red emission provides low background fluorescence and is compatible with various fluorescence-based detection methods. The compound is widely used for labeling antibodies and proteins. |
| ln Vivo |
Cyanine5 NHS ester chloride is not used as a therapeutic agent. Its in vivo utility is as a labeling reagent for fluorescence imaging applications. When conjugated to targeting ligands, the dye enables fluorescence imaging for tracking biodistribution and target engagement in animal models.
|
| Enzyme Assay |
In vitro labeling assays for Cyanine5 NHS ester chloride involve incubating the NHS ester with amine-containing biomolecules in appropriate buffers (typically pH 7-9). The reaction proceeds through nucleophilic attack of the primary amine on the NHS ester carbonyl, forming a stable amide bond. Labeling efficiency can be assessed by measuring the fluorescence intensity of the conjugated product.
|
| Cell Assay |
For in vitro cellular experiments, Cyanine5 NHS ester chloride is first conjugated to antibodies, proteins, or other targeting ligands via the NHS ester-amine reaction. The labeled conjugates are then purified and added to cell culture medium for incubation with target cells. After washing, cells are analyzed by fluorescence microscopy or flow cytometry. The far-red fluorescence provides low background and excellent signal-to-noise ratio.
|
| Animal Protocol |
For in vivo animal experiments, Cyanine5 NHS ester chloride is conjugated to targeting ligands and administered to animal models. The far-red emission provides good tissue penetration and low background fluorescence. Conjugates bearing Cy5 can be administered to animal models for tracking biodistribution and target engagement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cyanine5 NHS ester chloride have not been extensively characterized. The compound has a molecular weight of approximately 807.78 g/mol. It should be stored at -20°C, protected from light. The NHS ester is moisture-sensitive and should be handled under anhydrous conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cyanine5 NHS ester chloride has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
Cyanine5 NHS ester chloride is an amine-reactive NHS ester derivative of the Cyanine5 fluorophore, widely used for labeling antibodies, proteins, and other biomolecules. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C36H42CLN3O4
|
|---|---|
| Molecular Weight |
616.19
|
| Exact Mass |
615.286
|
| CAS # |
1032678-42-4
|
| Related CAS # |
Cyanine5 NHS ester iodide;Cyanine5 NHS ester bromide;1653991-59-3
|
| PubChem CID |
139592716
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
46
|
| Complexity |
1230
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1C2=C([H])C([H])=C([H])C([H])=C2C(C([H])([H])[H])(C([H])([H])[H])/C/1=C(\[H])/C(/[H])=C(\[H])/C(/[H])=C(\[H])/C1C(C([H])([H])[H])(C([H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[N+]=1C([H])([H])[H])=O)N1C(C([H])([H])C([H])([H])C1=O)=O
|
| InChi Key |
DOOTYHJFDNJMLS-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C38H46N3O4.ClH/c1-37(2)28-18-13-15-20-30(28)39(5)32(37)22-10-9-11-23-33-38(3,4)29-19-14-16-21-31(29)40(33)27-17-8-6-7-12-24-36(44)45-41-34(42)25-26-35(41)43;/h9-11,13-16,18-23H,6-8,12,17,24-27H2,1-5H3;1H/q+1;/p-1
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 8-[(2Z)-3,3-dimethyl-2-[(2E,4E)-5-(1,3,3-trimethylindol-1-ium-2-yl)penta-2,4-dienylidene]indol-1-yl]octanoate;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (405.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6229 mL | 8.1144 mL | 16.2288 mL | |
| 5 mM | 0.3246 mL | 1.6229 mL | 3.2458 mL | |
| 10 mM | 0.1623 mL | 0.8114 mL | 1.6229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
